{"schema_version":"1.0","type":"article","title":"55 億美元只差一步：Skyrizi 要接棒 Humira 當自體免疫藥王？","url":"https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king.md","lang":"zh-Hant","date":"2026-08-19","publish_at":"2026-08-19T08:00:00+08:00","updated_at":"2026-08-19","category":"商業分析系列","topic":"商業分析系列","tags":["Skyrizi","喜開悅","Humira","復邁","AbbVie","乾癬","自體免疫","IL-23","ICOTYDE"],"summary":"Skyrizi 2026 年第二季收入達 55.05 億美元，距 Humira 的歷史單季高點只差 7,400 萬美元；真正的接班考驗，是療效、治療負擔、多適應症與支付能力能否一起延續。","key_points":[],"facts":[],"sections":["01｜Humira 退場，AbbVie 又養出一個 55 億美元產品","02｜乾癬為什麼能養出超級重磅藥？","03｜它的王牌：清得乾淨，也把負擔壓低","04｜口服新藥來了，針劑就一定輸嗎？","05｜下一輪競爭，會比「針劑對口服」更複雜","結語｜下一個自體免疫藥王，比的是整套治療體驗","參考資料","免責聲明"],"references":[{"title":"[AbbVie 2026 年第二季財報]","source":"","date":"","url":"https://news.abbvie.com/2026-07-31-AbbVie-Reports-Second-Quarter-2026-Financial-Results"},{"title":"[AbbVie 2026 年第一季財報]","source":"","date":"","url":"https://news.abbvie.com/2026-04-29-AbbVie-Reports-First-Quarter-2026-Financial-Results"},{"title":"[AbbVie 2022 年第四季與全年財報]","source":"","date":"","url":"https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-full-year-and-fourth-quarter-2022-financial"},{"title":"[Skyrizi 美國 FDA 核准標籤]","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s044lbl.pdf"},{"title":"[ICOTYDE 美國 FDA 核准標籤]","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf"},{"title":"[Johnson & Johnson ICOTYDE 核准公告]","source":"","date":"","url":"https://www.investor.jnj.com/investor-news/news-details/2026/FDA-approval-of-ICOTYDE-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide/default.aspx"},{"title":"[美國成人乾癬盛行率原始研究]","source":"","date":"","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/"},{"title":"[Cosentyx 美國 FDA 核准標籤]","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125504s098lbl.pdf"},{"title":"[AbbVie 完成收購 Nimble Therapeutics]","source":"","date":"","url":"https://news.abbvie.com/2025-01-23-AbbVie-Completes-Acquisition-of-Nimble-Therapeutics"},{"title":"[AbbVie 2026 年 6 月免疫管線簡報（SEC 附件）]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926076067/tm2618365d1_ex99-2.htm"},{"title":"查證截止日：2026 年 8 月 11 日。","source":"","date":"","url":""}],"images":[{"alt":"圖 1｜Humira 與 Skyrizi 的歷史單季收入紀錄只差 7,400 萬美元","url":"https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king/figure-01.png"},{"alt":"圖 2｜Skyrizi 與 ICOTYDE 的療程及標籤試驗結果來自不同研究，不能直接判定誰贏","url":"https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king/figure-02.png"},{"alt":"圖 3｜自體免疫市場的決勝因素包括療效深度、治療負擔、共病安全與支付可近性","url":"https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-19）。55 億美元只差一步：Skyrizi 要接棒 Humira 當自體免疫藥王？。https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-19-skyrizi-humira-autoimmune-drug-king-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}